Alvotech will participate in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023. Our presentation is scheduled for Wednesday, November 15, 2023, at 1:00 pm GMT (8:00 am ET). To view the webcast go to: ow.ly/VLMp50Q4ZS4

The #CHMP has adopted a positive opinion for our AVT04 biosimilar candidate, the first for ustekinumab in Europe, an important step for patient access #biosimilars #HealthcareAccess #STADA Read all about it: ow.ly/xLWj50Q6suO

Health Canada has granted JAMP Pharma marketing authorization for our ustekinumab biosimilar candidate, the first in Canada. #biosimilars #HealthcareAccess #BioJAMP Read all about it: ow.ly/onec50Q7o7W

Meeting with investors at the Jefferies London Healthcare Conference. Our presentation will be streamed live today on our website at 1 pm GMT / 8 am ET. Register to view here: ow.ly/yc9K50Q7oq0 #JefferiesHealthcare #HealthAccess #biosimilars

Snow in Reykjavik 🎄 , the aroma of chocolate ☕ and Yule songs 🎅 filling the air. Today's winter solstice 🌄 heralds longer days. May your holidays be merry and bright.🙏

Ready for another whirlwind ride around the sun? After this extraordinary year, we can hardly wait! #366days #NewYear #2024

We are thrilled to receive European marketing authorization for our ustekinumab biosimilar, which STADA will market in Europe. ow.ly/tSkP50QpwBZ #biosimilars #HealthAccess

Women represent half of the world’s population, but remain underrepresented in the STEM fields. Alvotech has achieved and strives to maintain gender balance. Diversity increases the pool of talent, fresh perspectives, and creativity. #womeninscience #equality #diversity #STEM

We are happy to announce that market entry for our next biosimilar, AVT04 (ustekinumab) is expected in Canada in Q1, Japan in Q2 and Europe in Q3. Entry to the U.S. market will be in February 2025, pending FDA approval. ow.ly/gmx450QBUiT

We are pleased to announce FDA approval of the first high-concentration citrate-free interchangeable biosimilar adalimumab in the U.S. market. ow.ly/PIaB50QHSeA #healthcareaccess #biosimilars

Thanks to all who honored us by attending the Grand Opening for Alvotech's facility extension. Only 3 years passed since we broke ground and our staff has moved in. We are looking forward to telling you about R&D milestones and multiple global launches of our biosimilars.

Thanks to the many investors, partners, contractors and friends who joined us to celebrate 🎉 the opening of our Reykjavik facility extension last week, including the current and previous mayors of Reykjavik. #healthcareaccess #biotech #Reykjavik

Happy Easter from everyone at Alvotech. As we continue increasing access to affordable biologics, we look forward to sharing with you news of coming approvals, launches and filings. #biosimilars #biologics #healthcareaccess

Our second biosimilar has been approved by the FDA. A green light for the U.S. comes on the heels of approvals in other major global markets, Canada, Japan and Europe. Kudos to our partner, @tevausa. #healthcareaccess #biosimilars #biologics

Exciting results as we become the first company announcing positive topline results from a confirmatory patient study for a new biosimilar candidate in inflammatory disease. Marketing applications filed in major markets later this year. Read more: ow.ly/ogzN50Rn01L

Read more about our U.S. partnership agreement with Quallent Pharmaceuticals, which will distribute under private label Alvotech‘s interchangeable biosimilar, recently approved by the FDA for various autoimmune conditions such as rheumatoid arthritis. ow.ly/nwIV50RssOB

We are growing our partnership with Advanz Informatica-Pharma, signing a new European commercialization agreement for a biosimilar candidate in eye disease. #biosimilars #healthcareaccess. ow.ly/sKpc50SkMcN

We’ve released Alvotech’s Equality Report covering 2023, as a part of our broader corporate sustainability initiative. Check out how we are doing on our #ESG portal: ow.ly/kQPp50SxUJU. #equalpay #biosimilars #HealthcareAccess

We are heading to New York City for the Morgan Stanley 22nd Global Healthcare Conference this week. You can sign up and listen to a discussion with our management team on Thursday September 5, at 5:35 pm ET (21:35 GMT): ow.ly/nxZg50TcCTW

We're happy to share that Philip A. Caramanica, Chief IP Counsel and Deputy General Counsel, has been recognized as one of the world's leading IP strategists in IAM Patent Strategy 300 - for the second year in a row! #biosimilars #healthcareaccess